Translating cancer genome insights into practical clinical tools
Findings from complex statistical modelling can form the basis for easy-to-use precision diagnostic and risk-stratification tools to help inform management decisions
Studies present a wider application of sequencing techniques for the treatment of cancer
Whole-genome sequencing and single-cell sequencing can provide valuable insights not only in the identification of new therapy targets, but also to assess minimal residual disease and overcome treatment resistance
Liquid biopsies are quickly evolving beyond ctDNA, but technical challenges remain
Newly-presented studies highlight that insights into cancer can also be unlocked from circulating tumour cells, exosomal microRNA and cell-free RNA
Data from molecular analyses unveil diverse resistance mechanisms to endocrine therapy in breast cancer
Among the presented findings, a potential role for ESR1 gene fusions was observed
Innovation is leading to a comprehensive ‘map’ of tumours
Advances in spatial transcriptomics could provide novel opportunities for early detection, metastasis prediction and identification of actionable targets
Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
Translational research: from bytes to bedside
According to Prof. Serena Nik-Zainal, 2024 ESMO Translational Research Awardee it is important to change the mindset of the cancer community to embrace all the information available through genome research
Tumour-agnostic oncology – time has come to re-think clinical research
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
When to perform next-generation sequencing test in patients with cancer? ESMO updates its recommendations
NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies